Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novo Nordisk (NVO) to $42 from $43 and keeps an Underweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- NVO,LLY: Shares Drop as World Health Organization Calls for Cheaper Versions of Weight-Loss Drugs
- Novo Nordisk price target raised to DKK 340 from DKK 315 at BofA
- Novo Nordisk’s Stock Surges Amid Drug Breakthrough
- Trump Weekly: White House postpones healthcare proposal after backlash